The company's quadrivalent influenza virus subunit vaccine (for ages 3 and above) is now commercially available, while its pediatric version (for 6-35 months old) has completed Phase III clinical trials and entered the NDA registration and production stage. The 23-valent pneumococcal polysaccharide vaccine has completed Phase I clinical trials, and the freeze-dried human rabies vaccine (human diploid cell) is currently undergoing Phase I clinical trials. Multiple research achievements have been published in the internationally authoritative journal Vaccine and are consistently cited in China's annual Technical Guidelines for Influenza Vaccination.

The company's Phase I production park covers 69 acres with 80,000 square meters of GMP-compliant facilities, including production workshops, central laboratories, animal rooms, as well as supporting R&D buildings, power centers, and warehousing facilities that meet national standards. We have established internationally standardized production lines for influenza vaccines (both liquid and formulation workshops) and obtained both the Vaccine Production License and Experimental Animal Use License. The Phase II/III expansion (over 100 acres of newly added land) will enable industrial-scale production of all pipeline products. Holding 23 national registered trademarks, the company has been honored as: "2020 Potential Unicorn Enterprise in Jiangsu High-Tech Industrial Development Zone", "Gazelle Enterprise in Jiangsu High-Tech Zone", and "Top Ten Industrial Transformation and Innovation Investment Projects in Taizhou City".

Currently with over 600 employees, our core team consists of professionals from domestic and international biologics R&D and production fields, possessing decades of experience in vaccine development, manufacturing, testing, and management. The company has received: 1 national-level talent award, 1 Jiangsu Province "Double Innovation Talent" grant, 3 Jiangsu "113 Talents" high-level innovation awards, 1 high-level entrepreneurial talent award, and 1 special contribution talent project recognition.

Ab&B Bio-Tech operates on three fundamental principles: developing innovative vaccines (not imitations) aligned with global trends, protecting lives through healthcare solutions, and realizing our vision where China accesses global vaccine innovations while the world benefits from China-made quality vaccines. We uphold values of innovation, integrity, and perseverance to advance this mission.